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Park, Cardiff, UK; and 2Wales Kidney Research Unit, Cardiff University School of Medicine, Heath Park, Cardiff, UKPeritonitis remains the major obstacle for the maintenance
of long-term peritoneal dialysis and dysregulated host
peritoneal immune responses may compromise local anti-
infectious defense, leading to treatment failure. Whilst,
tissue mononuclear phagocytes, comprising macrophages
and dendritic cells, are central to a host response to
pathogens and the development of adaptive immune
responses, they are poorly characterized in the human
peritoneum. Combining ﬂow cytometry with global
transcriptome analysis, the phenotypic features and
lineage identity of the major CD14D macrophage and
CD1cD dendritic cell subsets in dialysis efﬂuent were
deﬁned. Their functional specialization was reﬂected in
cytokine generation, phagocytosis, and antigen
processing/presentation. By analyzing acute bacterial
peritonitis, stable (infection-free) and new-starter patients
receiving peritoneal dialysis, we identiﬁed a skewed
distribution of macrophage to dendritic cell subsets
(increasing ratio) that associated with adverse peritonitis
outcomes, history of multiple peritonitis episodes, and
early catheter failure, respectively. Intriguingly, we also
noted signiﬁcant alterations of macrophage heterogeneity,
indicative of different maturation and activation states that
were associated with different peritoneal dialysis
outcomes. Thus, our studies delineate peritoneal dendritic
cells from macrophages within dialysate, and deﬁne
cellular characteristics associated with peritoneal dialysis
treatment failure. These are the ﬁrst steps to unravelling
the detrimental adaptive immune responses occurring as a
consequence of peritonitis.
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1088P eritoneal dialysis (PD)-related peritonitis remains amajor cause of technique failure as well as mortality inmaintenance PD patients.1,2 In PD patients, the dialysis
exchange perturbs the tightly regulated tissue homeostasis
and composition of the immune cell population within the
peritoneal cavity.3 Previously, we have delineated the local
response to peritoneal infection–driven inﬂammation.4,5 Our
recent work has shown that repeated bacterial peritoneal
inﬂammation drives immune-mediated compromised tissue
repair response and ﬁbrosis.6 These data support the concept
that alterations in peritoneal immune cell composition in PD
patients may link to their adverse outcomes.
Tissue mononuclear phagocytes, comprised mainly of
macrophages (MØ) and dendritic cells (DC), are a key
tissue-resident component of the local immune system, with
roles including pathogen clearance, tissue repair, and antigen
presentation.7,8 Recent progresses in MØ/DC biology have
uncovered heterogeneity in these cell phenotypes, related to
different developmental origins and distinct differentiation
pathways.9–11 Studies on the phenotypic and functional
attributes of different tissue MØ/DC subsets in vivo have
highlighted that distinct subsets have specialized roles in
tissue homeostasis and local inﬂammation.12,13 In the
peritoneal cavity, studies have been largely focused on
MØ in mice. We, and others, have recently identiﬁed a
major, self-renewing population of tissue-resident macro-
phages, with roles in tissue homeostasis and response to
inﬂammation.14–16 On acute peritoneal inﬂammation
induced by Staphylococcus epidermidis supernatant in mice,17
neutrophils and monocytes are recruited into the inﬂamed
peritoneum. These inﬁltrated monocytes will differentiate
into MØ and/or DC and play effector functions locally
(i.e., phagocytosis and apoptotic cell clearance, antigen
presentation, and T-cell stimulation). In the ﬁeld of
PD, studies in late 1970s began to examine the cellular
composition of dialysis efﬂuent ﬂuids from noninfected
PD patients, and revealed the MØ as the predominant cell
type found in dialysis efﬂuent.18,19 Based on ex vivo and
in vitro functional analysis, peritoneal MØs are important in the
front line of host peritoneal defense in PD patients.20–23 It has
been suggested that peritoneal MØs from PD patients pheno-
typically and functionally resemble in vitro polarized macro-
phage colony-stimulating factor–driven “anti-inﬂammatory”
MØ or interleukin (IL)-4–driven alternatively activated MØ24,25;
however, so far the comprehensive genetic proﬁling and relatedKidney International (2017) 91, 1088–1103
Figure 1 | Phenotypic identiﬁcation of peritoneal mononuclear phagocyte subsets. (a) Representative density plots showing ﬂow-
cytometric gating strategies to identify peritoneal mononuclear phagocyte subsets within PD efﬂuent from stable dialysis patients
(upper panel) and day 1 peritonitis patients (lower panel). Myeloid cells were pregated on CD116þ populations after exclusion of doublets,
cellular debris, and dead cells. Within these cells, mononuclear phagocytes could be readily identiﬁed as HLA-DRþCD14þ/‒, and granulocytes
were HLA-DR‒CD14‒. The latter mainly comprised CD16high neutrophils (Neu), which substantially increased in number during acute peritonitis.
Mononuclear phagocytes could be segregated into 2 subsets: CD14þCD1clow/‒ (major) and CD1cþCD14low/‒ (minor). (b) Sorted CD14þ cells
and CD1cþ cells (the purity >95%) were cytospun, air-dried, and stained with Microscopy Hemacolor. The morphology of cells is shown
(bar ¼ 30 mm). Data derived from 1 patient representative of 4 stable patients. (c) Flow-cytometric analysis of select marker expression
by CD14þ cells and CD1cþ cells. Representative histogram plots are pregated as described previously. Shaded histograms depict (Continued)
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bas i c re sea r ch C-T Liao et al.: Mononuclear phagocyte phenotype during peritoneal dialysisbiological functional pathways of peritoneal MØ from PD
efﬂuents remains lacking and these conclusions overlook the
likely complex cell-cell heterogeneity. In contrast with the study
of peritoneal MØs, information on the DC component of the
human peritoneal cavity is sparse, especially in the context of
PD. Historically this fundamental knowledge-deﬁciency is
attributed to the paucity of speciﬁc markers needed for the
unambiguous identiﬁcation of this cell type.26 Overall, the lack
of detailed phenotypic and functional characterization of human
peritoneal mononuclear phagocytes has limited the investigation
of their specialized roles in the context of PD-related peritonitis,
immune dysfunction, and tissue damage.
To address this and to understand how the patient’s peri-
toneal immune system responds to pathogen invasion, we
ﬁrst aimed to deﬁne peritoneal mononuclear phagocyte
subsets, phenotypically and functionally during stable PD and
in patients experiencing peritonitis. Second, we longitudinally
monitored the kinetic changes of peritoneal MØ/DC subsets
in the new-starter PD patients to explore the patient’s
immune response to the catheter insertion surgery and dial-
ysis exchange.
We established novel criteria for the speciﬁc identiﬁcation
of distinct peritoneal MØ/DC subsets in PD patients. This has
permitted a comprehensive analysis of their heterogeneity and
we have deﬁned the immunological differences between
the cell types by global transcriptome analysis and speciﬁc
functional assessment. Finally, we demonstrate that there are
alterations of phenotypic distribution of peritoneal mono-
nuclear phagocyte subsets under deﬁned clinical settings,
which are associated with patient outcomes.RESULTS
Phenotypic identiﬁcation of 2 distinct peritoneal
mononuclear phagocyte subsets
Although detailed analysis of the composition of leukocyte
subpopulations within the PD efﬂuents has improved,27 the
phenotypic characterization of mononuclear phagocytes is
still relatively poor. Here, we used a novel ﬂow-cytometric
gating strategy based on CD116 (granulocyte-macrophage
colony-stimulating factor receptor alpha) expression
(Figure 1a), a “pan-myeloid lineage” cell marker, which has
been used effectively in mice.28 Together with human
leukocyte antigen–antigen D related (HLA-DR) (major his-
tocompatibility complex class II molecule) and CD14
(a coreceptor for lipopolysaccharide), CD116þ myeloid cells
could be separated into HLA-DRþCD14þ/‒ mononuclear
phagocytes and HLA-DR‒CD14‒ granulocytes. The latter,
discussed in more detail later in this article, mainly comprised
CD16high neutrophils that substantially increased in number=
Figure 1 | (Continued) receptor-speciﬁc staining and bold lines denote is
of 42 stable patients giving similar results. (d) Bar graphs shown were qu
ﬂuorescence intensity (MFI) between receptor-speciﬁc and isotype contro
and CD1cþ cells under stable status (upper) and during peritonitis (lower
and were analyzed using paired t test.
1090during acute bacterial peritonitis (Figure 1a). Notably, 2
distinctive mononuclear phagocyte subsets could be recog-
nized by the additional staining of CD1c antigen (blood
dendritic cell antigen 1):CD14þCD1clow/‒ and CD1cþ
CD14low/‒. Both subsets were morphologically monocytic in
appearance, but CD1cþ cells were smaller in size with less
cytoplasm (Figure 1b). Phenotypically, CD14þ cells displayed
higher CD11b, CD16 (FcgRIII), and CD163 expression,
whereas CD1cþ cells had higher CD11c, Fc 3R1a, and CD206
(mannose receptor) expression; both subsets are CCR2þ
(Figure 1c). Examination of the dialysate of PD patients with
acute bacterial peritonitis revealed similar marker expression
when compared with stable patients without peritonitis
(Figure 1d).Transcriptional proﬁling delineates the identities of
mononuclear phagocyte subsets
To determine how distinct the CD1cþ cells were, we analyzed
the transcriptome of the CD14þ and CD1cþ subsets puriﬁed
from uninfected PD efﬂuent of stable patients (n ¼ 5).
Microarray data identiﬁed a unique transcriptional proﬁle of
differentially expressed genes in each cell subset (Figure 2a).
Notably, the CD1cþ subset displayed signiﬁcantly higher FLT3
(Fms-related tyrosine kinase 3) and IRF4 (Interferon Regu-
latory Factor 4) expression, both of which are involved in DC
development,29,30 whereas the CD14þ subset had higher
MAFB (V-maf musculoaponeurotic ﬁbrosarcoma oncogene
homolog B) expression, which is associated with MØ differ-
entiation (Figure 2b).31 Canonical pathway analysis further
revealed differentially expressed genes in CD1cþ cells were
more involved in DC maturation and antigen presentation,
whereas CD14þ cells were enriched in differentially expressed
genes associated with cholesterol biosynthesis, eicosanoid
signaling, and the complement system (Supplementary
Figure S1). Together, these data implied that the CD1cþ
subset could be the “bona-ﬁde DC” subset in the human
peritoneal cavity, whereas the CD14þ subset had a tran-
scriptional proﬁle characteristic of “traditional MØs.”
Furthermore, CD14þ MØs and CD1cþ DCs exhibited
distinctive expression proﬁles in a number of biological
processes, as exempliﬁed by those involving in leukocyte
migration, responses to bacteria, and T-cell stimulation
(Figure 2c). Additionally, there were evident differences in
genes involved in pathogen recognition (Toll-like receptors,
c-type lectin receptors), receptor-mediated endocytosis/
phagocytosis (scavenger receptors, Fc receptors), chemokine
or cytokine system, and antigen presentation (Supplementary
Figure S2). Of note, CD14þ MØs had higher CD36, CD64,
MerTK (MER proto-oncogene, tyrosine kinase) expression,otype control staining. Data are derived from 1 patient representative
antiﬁcation of receptor expression, measured as difference in medium
l staining. Quantitative comparisons were made between CD14þ cells
). Data are shown as mean  SEM of indicated number of patients (n)
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Figure 2 | Transcriptional proﬁling of 2 distinct peritoneal mononuclear phagocytes. Gene expression proﬁles of puriﬁed peritoneal
CD14þ cells and CD1cþ cells within PD efﬂuent from 5 stable dialysis patients were analyzed by Affymetrix microarrays (Affymetrix GeneChip
Human Gene 1.0 ST Array). (a) Venn diagram showing the number of the differentially expressed gene probesets identiﬁed via microarray
analysis (ﬁltered by adjusted P < 0.05). Among 5324 identiﬁed gene probesets, 4797 gene probesets are identiﬁed as less than 2 fold (Continued)
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bas i c re sea r ch C-T Liao et al.: Mononuclear phagocyte phenotype during peritoneal dialysiswhereas CD1cþ DCs displayed higher CD226 and CLEC10A
(CD301) expression; and these were validated by ﬂow
cytometry through speciﬁc staining of these surface molecules
(Figure 2d). Interestingly, recent studies show that these
markers are useful for phenotyping multiple tissue MØ/DC
subsets in mice.17,32
Peritoneal DC maturation during bacterial peritonitis
Upregulation of costimulatory molecules, CD80 and CD86,
on mature DCs is important for antigen presentation and
T-cell activation. Our transcriptomic data revealed that
CD1cþ DCs express higher levels of CD80 and CD86 than
CD14þ MØs (Figure 3a, left panels). Notably, signiﬁcantly
increased expression of CD80 and CD86 expression in CD1cþ
DCs was observed during acute bacterial peritonitis,
compared with stable status (Figure 3a, middle and right
panels). Additionally, peritoneal DCs exhibited higher CCR7
(C-C motif chemokine receptor 7) expression than MØs
(Figure 3b, left panel). CCR7 is important for tissue DC
migration to draining lymph nodes, where mature DCs could
activate T cells to initiate their effector functions.33 Impor-
tantly, considerable upregulation of CCR7 in DCs was
observed on ex vivo lipopolysaccharide stimulation, implying
that some DCs would acquire migratory properties during
maturation (Figure 3b, middle and right panels).
Characteristic functional specialization of peritoneal MØ
and DC
To functionally validate our ﬁndings, we performed
ex vivo analysis of peritoneal MØ and DC from infection-
free PD efﬂuents. On 7-hydroxy-9H-(1,3-dichloro-9,
9-dimethylacridin-2-one)–labeled S epidermidis challenge,
CD14þMØs displayed higher capacity of phagocytosis as well
as generated more reactive oxygen species (detected by
3’-[p-aminophenyl] ﬂuorescein), compared with CD1cþ DCs
(Figure 4a and 4b). To test their ability to uptake, process, and
present speciﬁc antigen to responder T cells, a modiﬁed
in vitro assay of cross presentation was conducted.34 The
results suggested that both cell types are effective antigen-
processing and -presenting cells, albeit CD1cþ DCs are
more efﬁcient than CD14þ MØs in this regard (Figure 4c
and 4d). To investigate the cellular responses to microbial
stimuli, the production of the proinﬂammatory cytokines
(tumor necrosis factor-a, IL-1b, IL-6, IL-12p40/p70) and
anti-inﬂammatory cytokine (IL-10) were measured by=
Figure 2 | (Continued) changes between CD14þ cells and CD1cþ cells. T
cells (compared with CD1cþ cells), whereas 300 gene probesets upregula
Expression of mRNA encoding FLT3, IRF4 (both for “DC development”) an
Heat maps representing the relative gene expression of immune functio
and “T-cell stimulation.” Differentially expressed genes selected for analy
cells or vice versa, and then clustered on heat maps. (d) Flow-cytometric
Representative histogram plots are pregated as described in Figure 1. (U
bold lines denote isotype control staining. Data are derived from 1 patien
were quantiﬁcation of receptor expression, measured as the difference i
isotype control staining. Quantitative comparisons were made between C
are shown as mean  SEM and were analyzed using paired t test.
1092intracellular ﬂow cytometry after ex vivo stimulation with
lipopolysaccharide or S epidermidis supernatant4
(Supplementary Figure S3A). Both CD14þ MØ and CD1cþ
DC could generate signiﬁcant amounts of tumor necrosis
factor-a, IL-1b, and IL-6, as well as small amounts of IL-10
and IL-12p40/p70 after stimulation (Supplementary
Figure S3B), albeit that CD14þ MØs generated higher tu-
mor necrosis factor-a and IL-6 levels than CD1cþ DCs on
either ex vivo S epidermidis supernatant or lipopolysaccharide
stimulation.
Heterogeneous macrophage activation and
monocyte-to-macrophage maturation in PD patients
Macrophages retain a substantial phenotypic plasticity,
reﬂected by their heterogeneous activation and maturation
status under different microenvironments. We observed that
CD14þ MØs from PD efﬂuent, unlike CD1cþ DCs, displayed
variable CD16 and CD206 expression (Figure 5a). Both CD16
and CD206 have been adopted as surface markers indicative
of macrophage activation or monocyte-to-macrophage
maturation.35–37 Based on these 2 markers, CD14þ MØs
could be stratiﬁed into 4 subtypes: CD16þCD206þ,
CD16þCD206‒, CD16‒CD206þ, CD16‒CD206‒ (Figure 5a),
most likely representing different stages of MØ activation
and maturation within the peritoneal cavity. Of note,
CD16þCD206þ subtype expresses the highest levels of
HLA-DR and CD163 (“mature phenotype”), whereas
CD16–CD206–subtype expresses the lowest levels of these
surface antigens (“immature phenotype”) (Figure 5b).
CD16þCD206– and CD16–CD206þ MØs potentially repre-
sent cells of intermediate phenotype.
Distinct patterns of myeloid cell distribution associate with
patient outcomes
The composition of peritoneal leukocyte subpopulations is
altered under different clinical settings.27 Here, our data
revealed that peritoneal neutrophils, MØs, and DCs signif-
icantly increased in the infected ﬂuids from acute bacterial
peritonitis, compared with infection-free ﬂuid samples
from stable dialysis patients (Figure 6a). With regard to
MØ heterogeneity, there was a signiﬁcantly higher
CD16‒CD206‒ subtype (%) and lower CD16þCD206þ
subtype (%) within the infectious ﬂuids, compared with
infection-free ﬂuids (Figure 6a, right panel). Interestingly,
in patients with acute bacterial peritonitis, the increasehere are 227 gene probesets upregulated $2 fold changes on CD14þ
ted $2 fold changes on CD1cþ cells (compared with CD14þ cells). (b)
d MAFB (“MØ development”) indicated by the Affymetrix analysis. (c)
nal pathways, including “leukocyte migration,” “response to bacteria,”
sis were based on fold change $2, either CD14þ cells versus CD1cþ
analysis of select marker expression by CD14þ MØs and CD1cþ DCs.
pper panels) Shaded histograms depict receptor-speciﬁc staining and
t representative of 7 stable patients. (Lower panels) Bar graphs shown
n medium ﬂuorescence intensity (MFI) between receptor-speciﬁc and
D14þ MØs and CD1cþ DCs from stable dialysis patients (n ¼ 7). Data
Kidney International (2017) 91, 1088–1103
Figure 3 | Peritoneal dendritic cell maturation on peritoneal infections. (a) (Left graphs) Microarray analysis showing differential expression of
CD80 and CD86 genes between CD14þ MØ and CD1cþ DC. Data derived from 5 individual stable patients were analyzed by t test with multiple
adjustment. (Middle panels) Representative histogram plots depicting ﬂow-cytometric analysis of surface expression of CD80 and CD86 on CD14þMØ
and CD1cþ DC, respectively, from stable dialysis and peritonitis (day 1) patients. Data represent 1 of a total 20 stable patients and 1 of a total
20 peritonitis patients. (Right graphs) Quantiﬁcation of CD80 and CD86 expression, measured as difference in medium ﬂuorescence intensity (MFI)
between receptor-speciﬁc and isotype control staining. Quantitative comparisons were made between CD14þ cells and CD1cþ cells under stable
status (n¼ 20) and during peritonitis (n¼ 20). Data are shown as mean SEM and were analyzed using 2-way analysis of variance (ANOVA) with the
Tukey multiple comparisons test. (b) (Left graph) Microarray analysis showing differential expression of CCR7 gene between CD14þ MØ and CD1cþ
DC. Data derived from 5 individual stable patients were analyzed by t test with multiple adjustment. (Middle panels) Representative histogram plots
depicting ﬂow-cytometric analysis of surface expression of CCR7 on CD14þ MØ and CD1cþ DC, respectively, with and without ex vivo lipopoly-
saccharide stimulation for 24 hours. Data represent 1 of 7 stable patients. (Right graph) Quantitative comparisons of CCR7 expression (DMFI) were
made between CD14þ cells and CD1cþ cells with and without ex vivo lipopolysaccharide stimulation (n ¼ 7). Data are shown as mean  SEM and
were analyzed using 2-way analysis of variance (ANOVA) with the Tukey multiple comparisons test. ns, P $ 0.05; *P < 0.05; **P < 0.01; ***P < 0.001.
C-T Liao et al.: Mononuclear phagocyte phenotype during peritoneal dialysis ba s i c re sea r chin CD14þ MØs was much greater than CD1cþ DCs, and
the ratio of MØ to DC skewed up signiﬁcantly in perito-
nitis samples. There was no difference between gram-
positive peritonitis and gram-negative peritonitis in thisKidney International (2017) 91, 1088–1103regard (Figure 6b); however, PD ﬂuids from gram-
negative peritonitis contained slightly more CD16‒
CD206‒ MØ and less CD16þCD206‒ MØ than those
from gram-positive peritonitis (Figure 6b, right panel).1093
Figure 4 | Functional characterization of peritoneal macrophages and dendritic cells. (a) Representative ﬂow-cytometric density plots
showing the generation of reactive oxygen species from peritoneal MØ/DC, detected by 3’-(p-aminophenyl) ﬂuorescein (APF), following challenges
with 7-hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one) (DDAO)-conjugated Staphylococcus epidermidis (S.E) ex vivo or cultured in medium
only. The percentages of cells found in each of speciﬁed gate are indicated. (b) Quantiﬁcation of bacterial uptake by respective monocytic cells (left
graph) and positive APF staining (%) within the cells phagocytosing DDAO-S.E (right graph). Data are representative of 4 stable PD patients and
were analyzed by paired t test. (c) Representative density plots show ﬂow-cytometric determination of intracellular interferon (IFN)-g production
by responder CD8þ T cells speciﬁc for M1p58-66. Plots display responder T cells after co-culture with CD14þ MØ or CD1cþ DC (from HLA-A2þ
stable PD patients), which were loaded with soluble Flu-M1 protein, or pulsed with Flu-M1p58–66 peptide (at an MØ/DC:responder ratio of 1:1–2).
Phorbol myristate acetate (10 mg/ml) þ Ionomycin (1 mM) was used as a positive control. Data are representative of 1 from 4 stable PD patients. (d)
Quantiﬁcation of intracellular IFN-g expression from responder T cells derived from antigen processing and presentation assay based on loading
Flu-M1 protein antigen on the respective MØ or DC. Data are representative of 4 stable PD patients and were analyzed by paired t test.
bas i c re sea r ch C-T Liao et al.: Mononuclear phagocyte phenotype during peritoneal dialysisImportantly, unresolved/refractory peritonitis episodes were
associated with signiﬁcantly higher numbers of peritoneal
neutrophils, MØs as well as higher ratio of MØ to DC than
successfully treated ones (Figure 6c). There was also no1094signiﬁcant difference in MØ heterogeneity between suc-
cessfully treated peritonitis and failed cases (Figure 6c, right
panel). To examine the impact of peritonitis history on the
distribution of peritoneal myeloid subsets, we comparedKidney International (2017) 91, 1088–1103
Figure 5 | Heterogeneous activation and maturation of peritoneal macrophages under different clinical settings. (a) Representative ﬂow-
cytometric density plots (left) and histogram plots (right) showing the segregation of CD14þ MØs (orange) and CD1cþ DCs (blue) under stable
status (upper panel) and during peritonitis (lower panel). Contrast to CD1cþ DCs with CD16low/‒ and CD206high/þ, CD14þ MØs could be
subgated into CD16þ and CD16‒, each further stratiﬁed into C206‒ and CD206þ, resulting into 4 MØ subtypes. Data are representative of the
analysis of 42 stable and 42 peritonitis patients, and the same approach was applied through all analyzed PD samples in this study. (b) Bar
graphs comparing HLA-DR and CD163 expression, measured as the difference in medium ﬂuorescence intensity (MFI) between receptor-
speciﬁc and isotype control staining, among individual 4 peritoneal MØ subtypes from PD patients under stable dialysis (left, n ¼ 20) and during
acute bacterial peritonitis (right, n ¼ 20). Data are shown as mean  SEM and was analyzed by 1-way analysis of variance tests.
C-T Liao et al.: Mononuclear phagocyte phenotype during peritoneal dialysis ba s i c re sea r chstable dialysis patients without history of peritonitis and
those with only 1 episode or multiple episodes, showing that
there was a higher number of peritoneal MØs and a higher
MØ-to-DC ratio in patients with multiple episodes of
peritonitis, compared with those without any history of
peritoneal infection (Figure 6d). The former also has a
signiﬁcantly higher proportion of CD16þCD206‒ MØ than
the latter (Figure 6d, right panel).Kidney International (2017) 91, 1088–1103Myeloid cell distribution and macrophage heterogeneity
during longitudinal follow-up in “new-starter” PD patients:
impact of catheter surgery and dialysis intervention
To understand how the patient’s peritoneal immune system
responds to an acute insult (catheter implantation surgery) and
the subsequent intervention by continuous dialysis exchange,
we longitudinally followed a cohort of 50 “new-starter”
PD patients for at least 1 year (Supplementary Figure S4).1095
Figure 6 | Distribution of peritoneal myeloid subsets under different clinical settings. Graphs showing the comparisons of peritoneal
neutrophils, CD14þ MØs, CD1cþ DCs (in actual number), the ratio of MØ to DC, and the percentage of each MØ subtype within CD14þ MØs, (a)
between stable PD patients (n ¼ 42) and day 1 bacterial peritonitis patients (n ¼ 42). (b) Among gram-positive (G[þ], n ¼ 29), gram-negative
(G[‒], n ¼ 10), and mixed G(þ)/G(‒) peritonitis (n ¼ 3). (c) Between the peritonitis episodes with treatment success (n ¼ 33) and (Continued)
bas i c re sea r ch C-T Liao et al.: Mononuclear phagocyte phenotype during peritoneal dialysis
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C-T Liao et al.: Mononuclear phagocyte phenotype during peritoneal dialysis ba s i c re sea r chBased on a similar ﬂow-cytometry approach, we were able to
phenotypically identify distinct myeloid subsets including
neutrophils, eosinophils, and mononuclear phagocytes
(MØ/DC) within the serial collections of PD ﬂuids
(Supplementary Figure S5). Despite general decline in the
numbers of all myeloid subsets along the course of PD
therapy, the proportion of peritoneal mononuclear phago-
cytes increased, especially after continuous dialysis started
(Supplementary Figure S6A and S6B). Intriguingly, CD14þ
MØ decreased continuously along the course of PD therapy,
whereas CD1cþ DC maintained a stable number during the
predialysis as well as early dialysis period, then declined at a
relatively slow rate as dialysis continued, hence resulting in
the relative increase in the percentage of CD1cþ DC recov-
erable from the tissue (Figure 7a). The ratio of CD14þ MØ
to CD1cþ DC decreased during the predialysis period and
gradually reached stable status after 6-month dialysis
(Figure 7a, right panel). Within the CD14þ MØ, the main
alteration along the course of PD therapy was the increase in
the proportion of CD16þCD206‒ MØ but decrease in
CD16þCD206þ mature subtype (Figure 7b). Irreversible
catheter dysfunction/obstruction is a major cause for early
technique failure (< 3-month dialysis), as shown in
Supplementary Figure S4. Interestingly, compared with
patients without catheter failure, those with catheter failure
had signiﬁcantly higher numbers of peritoneal neutrophils
as well as higher ratio of MØ to DC (Figure 7c) from their
ﬁrst PD ﬂush. Additionally, there was a signiﬁcantly higher
proportion and number of CD16þCD206‒ MØ subtype in
patients with catheter failure at ﬁrst PD ﬂush, and also
during the predialysis period (Figure 7d).DISCUSSION
This study has demonstrated that human peritoneal mono-
nuclear phagocytes from PD patients are a heterogeneous
population. Distinct peritoneal monocytic subpopulations
most likely represent different developmental origins, differ-
entiation pathways, and activation/maturation states. Impor-
tantly, for the ﬁrst time, we could identify human peritoneal
DCs within the PD efﬂuent, which are morphologically,
phenotypically, transcriptomically and functionally distinct
from the MØs. Our observations also suggested that the
alterations of peritoneal MØ/DC distribution and MØ acti-
vation/maturation status may indicate a unique scenario
and/or severity of i.p. inﬂammation, which in turn can be
linked to patients’ clinical outcomes.
Previous studies in PD patients mainly focused on peri-
toneal MØ biology (mainly CD14þ cells) and only a very few=
Figure 6 | (Continued) those with treatment failure (n ¼ 9). (d) Among
only 1 episode of peritonitis (n ¼ 10) and those with more than 1 episod
group. Data were analyzed for statistical signiﬁcance by Mann-Whitney
parison) with Dunn’s multiple comparison post-tests (asterisks) indicated
bars denote SEM. Data were analyzed by 2-way analysis of variance (ANO
subtype; P, stable patients with or without history of peritonitis; Tx, trea
Kidney International (2017) 91, 1088–1103studies attempted to address peritoneal DCs, with no clear
identiﬁcation of this important cell type. Our application of
multicolor ﬂow cytometry has identiﬁed a CD1cþ DC pop-
ulation within the PD efﬂuent. These, not only display
distinctive surface marker proﬁles to CD14þ MØ, but have
unique transcriptional proﬁles, illustrating their specialized
functional properties. These data have provided new insights
into their individual roles in the regulation of peritoneal
immunity against invading pathogens. Brieﬂy, blood mono-
cytes are rapidly recruited into peritoneal cavity on peritonitis
(Figure 8), presumably depending on the chemotactic
gradient generated by the inﬂamed peritoneum, including,
for example, C-C motif chemokine ligand 2/Monocyte che-
moattractant protein-1.38 These newly arrived monocyte/
MØs play a key effector role in bacterial eradication; produce
inﬂammatory mediators, such as tumor necrosis factor-a,
IL-1b, IL-6; and possibly relate to severe tissue inﬂammation
and adverse outcomes (see later in this article). On arrival,
these monocyte-derived MØs undergo a maturation process
(increased expression of CD206, CD163, and HLA-DR),
which is potentially hampered by the commencement and
continuation of dialysis exchange, as shown by data from the
“new-starter” patient cohort. With regard to peritoneal
CD1cþ DCs, 2 potential origins are identiﬁed: direct migra-
tion of blood CD1cþ DC precursors, and monocyte-to-DC
differentiation (monocyte-derived DCs) (Figure 8). Without
the ability to perform fate-mapping studies in patients, we
rely on the nomenclature classiﬁcations of Guilliams et al.39 to
deﬁne our CD1cþ DC population. The expression of CD1c,
CD1a, CD11b, CD206 (conﬁrmed by ﬂow-cytometry and
microarray analysis) and high expression of C-X3-C motif
chemokine receptor 1 (microarray data, not shown), argue
against a conventional/classical DC1 assignment. Additionally,
the very low-low CD14, CD16, CD64, MERTK (the latter
from comparison of microarray data to CD14þ MØ
[Supplementary Figure S2]), and relatively high Tool-like
receptor 3 expression (Supplementary Figure S2) support a
cDC2 assignment instead of monocytic origin. This DC
versus monocytic assignment is also supported by the relative
expression of FLT3, IRF4, and MAFB (Figure 2b). Interest-
ingly, our recent identiﬁcation of an analogous population of
antigen-presenting cells in mice permitted fate-mapping and
factor-dependency studies that also supported the assignment
of the cDC2 nomenclature.17
Intriguingly, the increase in CD1cþ DC number is very
limited during peritonitis, compared with CD14þ MØs. One
possible explanation is that the local microenvironment may
favor monocyte inﬂux, rather than DC precursor migration
and/or in situ monocyte-to-DC differentiation. Hence, thestable PD patients without history of peritonitis (n ¼ 22), those with
e of peritonitis (n ¼ 10). Horizontal bars denote the medium of each
U tests (2-group comparison) or Kruskal-Wallis tests (3-group com-
where signiﬁcant. For bar graphs, data were shown as mean, and error
VA) tests with Sidak’s multiple comparisons test. I, interaction; C, cell
tment.
1097
Figure 7 | Myeloid cell distribution and macrophage heterogeneity during longitudinal follow-up in “new-starter” PD patients. The
compositions of mononuclear phagocyte subsets and MØ subtypes in peritoneal efﬂuents have been analyzed from 1 week after PD catheter
surgery to the end of the ﬁrst year of PD treatment. Each patient would have 6 time points of PD ﬂuid sampling if he or she could maintain
PD therapy for at least 1 year. In total, 171 samples have been analyzed: 50 samples from 1st ﬂush (1 week after catheter surgery), (Continued)
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Figure 8 | Summary of cellular kinetics of peritoneal MØ and DC under stable dialysis and on bacterial peritonitis. Schematic diagram
depicting the proposed cellular kinetics of peritoneal MØs and DCs under stable dialysis and on bacterial peritonitis. Peritoneal mononuclear
phagocytes from PD efﬂuent comprise CD14þ MØs (predominant population) and CD1cþ DCs. Under stable status, PD ﬂuid exchange
would diminish the resident population within the peritoneal cavity. Blood monocytes were then recruited into the peritoneal cavity, where
they undergo maturation process (represented by increased expression of HLA-DR, CD163, and CD206). However, this process is hindered
by the dialysis exchange (washing out the mature MØs leading to a relative enrichment of the cavity with the newly recruited immature
ones), perhaps compounded by dilution of cytokine/growth factor essential for MØ maturation. Acute peritonitis is associated with a marked
elevated inﬂux of immature MØ in the context of continued dialysis. On the other hand, peritoneal CD1cþ DCs could be supplied by
2 sources: recruitment of blood CD1cþ DC precursors and in situ monocyte/MØ-to-DC differentiation. On bacterial peritonitis, the relatively
immature peritoneal DCs become activated and acquire a more mature phenotype (represented by increased expression of CD80 and CD86).
Although some mature DCs may stimulate peritoneal naïve T cells locally, others bearing with upregulated CCR7 expression may migrate
to local lymph nodes to initiate a systemic adaptive immune response. Meanwhile, monocytes are rapidly recruited into the peritoneal
cavity, where (alongside neutrophils) their functions likely include execution of the bactericidal activity and clearance of apoptotic cells
and tissue debris.
=
Figure 7 | (Continued) 37 samples from 2nd ﬂush (2–3 weeks after 1st ﬂush), 39 samples from PD start (normally 1 week after 2nd ﬂush),
20 samples from PD for 3 months, 15 samples from PD for 6 months, and 10 samples from PD for 1 year. (a) Graphs showing the numbers (left)
and the proportion (central) of CD14þMØs and CD1cþ DCs within peritoneal mononuclear phagocytes as well as the ratio of MØ over DC (right)
changed during the ﬁrst year of PD therapy. (b) Graphs showing the cell number (left) and the proportion (right) of each MØ subtype changed
during the ﬁrst year of PD therapy. (c) Graphs showing the comparisons of peritoneal neutrophils, MØ and DC (in number) from the ﬁrst
PD ﬂush efﬂuents between patients without (n ¼ 32) and with catheter failure (n ¼ 9). Horizontal bars represent the mean. Data were analyzed
by Student t test (if parametric) or Mann-Whitney U test (if nonparametric). (d) (Left panels) Graphs showing the proportion (upper) and the
actual number (lower) of each MØ subtype from the 1st PD ﬂush of “new-starter” patients without (n ¼ 32) and with catheter failure (n ¼ 9).
Data were shown as mean  SEM. Data were analyzed by 2-way ANOVA tests with Sidak multiple comparisons test. (Right panels) Graphs
depicting the change of the proportion (upper) and the actual number (lower) of CD16þCD206‒ MØ subtype from the 1st PD ﬂush to PD start of
“new-starter” patients without (n ¼ 32 for 1st ﬂush, n ¼ 25 for 2nd ﬂush, n ¼ 27 for PD start) and with catheter failure (n ¼ 9 for 1st ﬂush, n ¼ 4
for 2nd ﬂush, n ¼ 4 for PD start). Data are shown as mean  SEM. Data were analyzed by 2-way analysis of variance (ANOVA) tests.
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Additionally, CD1cþ DCs maintained a relatively stable
number in the predialysis phase and appeared more resistant
to the dialysis depletion, which was in contrast to CD14þ
MØs. These distinctive kinetics of CD14þ MØs and CD1cþ
DCs during the course of PD therapy, as well as peritonitis
episodes, has implied a different recruitment or differentia-
tion processes, driven by local cytokines/chemokines under
steady state and during inﬂammation. Nonetheless, these DCs
may acquire a mature phenotype on infectious challenge,
resulting in increased antigen-presenting capability (upregu-
lated CD80/CD86 expression) for T-cell stimulation locally,
or systemically through migration of CCR7þ DCs to draining
lymph nodes. Notably, a previous study within our unit
revealed that there is a substantial enrichment of the effector
memory T-cell subset within PD efﬂuent from stable PD
patients40; perhaps this could be linked to the role of peri-
toneal DCs in establishing local adaptive immunity. Related, a
recent study investigating peritoneal MØ/DC subsets within
tumor ascites from patients with advanced ovarian cancer
also identiﬁed CD14þ MØs and CD1cþ DCs, through a
different ﬂow-cytometric gating approach.41 Comparison of
the transcriptome datasets demonstrates important correla-
tions (Supplementary Figure S7).
The present study indicates that changes in peritoneal
MØ/DC distribution and MØ activation/maturation status
in PD patients may indicate the severity of i.p. inﬂamma-
tion. For example, patients with peritonitis failure had
higher ratios of MØ to DC than those with good prognosis.
Similarly, “new-starter” PD patients with catheter failure
had higher ratios of MØ to DC than those without failure.
These ﬁndings suggested that higher ratios are associated
with more severe i.p. inﬂammation. The trend also could be
observed in stable patients with a history of multiple peri-
tonitis episodes, when compared with patients with no
history of peritonitis. Notably, a recent observational study
revealed that stable dialysis patients with a history of peri-
tonitis had higher levels of dialysate MCP-1, compared with
those without any history of peritonitis.42 Hence, the
increased MØ accumulation (and also the MØ-to-DC ratio)
within PD efﬂuent may reﬂect chronic peritoneal inﬂam-
mation after recurrent peritonitis. These recruited MØs
could generate signiﬁcant amounts of proinﬂammatory
cytokines on infectious challenges, and so potentiate the
development of membrane ﬁbrosis, similar to the results
found in our Th1-driven repeat-hit S epidermidis
supernatant-induced experimental peritoneal ﬁbrosis
model.6 Furthermore, heterogeneous MØ activation/matu-
ration status was observed under different clinical scenarios
and potentially related to patient outcomes. For example,
there is a trend of increased proportion of CD16‒CD206‒
MØ subtype in gram-negative peritonitis and failed peri-
tonitis treatment, whereas increased proportion of
CD16þCD206‒ MØ subtype in “new-starter” patients with
catheter failure and stable patients with history of repeated
peritonitis. Interestingly, after catheter implantation, but1100before continuous dialysis begins, the CD16þCD206þ is
seen to be the largest MØ subset, reﬂecting an accumulation
of mature cells. In the future, it would be interesting to
investigate how these altered MØ/DC distributions and MØ
activation/maturation states correlate to membrane
dysfunction/ﬁbrosis in patients receiving long-term PD.
Indeed, the importance of this connection has been
addressed very recently.43 By transcriptional proﬁling of
peritoneal tissues from PD patients with encapsulating
peritoneal sclerosis, those without encapsulating peritoneal
sclerosis or uremic patients without history of PD, the
pathway analysis of the differentially expressed genes has
revealed enrichment in several pathways relating to MØ/DC
function and activation/maturation in patients developing
encapsulating peritoneal sclerosis.
In summary, the present study has provided a broad
insight into peritoneal MØ/DC biology in PD patients.
Through deciphering the complexity of phenotypic and
functional heterogeneity of these cells, the speciﬁc role of
individual MØ/DC subsets in the context of peritonitis as well
as alterations after catheter implantation and dialysis inter-
vention have been demonstrated, and links between MØ/DC
biology and patient outcome described.
METHODS
Patients
Patients were recruited from the PD unit at University Hospital of
Wales in Cardiff, UK. A total of 42 episodes of acute bacterial
peritonitis were included in this study. The causative
organism(s) and the treatment outcome of peritonitis episodes were
recorded. The outcome of peritonitis treatment was categorized into
“treatment success” or “treatment failure” (deﬁned as peritonitis-
related mortality or technique failure with permanent transfer to
hemodialysis). Meanwhile, 42 stable patients under maintenance PD
therapy for more than 6 months were enrolled for comparisons.
These patients were free from peritonitis for at least 3 months at the
time of PD ﬂuid sampling. Additionally, a cohort of “new-starter”
PD patients (n ¼ 50) was longitudinally followed for at least 1 year.
Patient outcomes such as nondeath technique failure, deaths, or
receiving transplantation were documented. This study was under-
taken according to principles described in the Declaration of
Helsinki and under the local ethical guidelines (Bro Taf Health
Authority, Wales) and approved by the South East Wales Local Ethics
Committee (COREC:04WSE04/27). All patients provided written
informed consent.
Isolation of peritoneal cells
Peritoneal cells were harvested either from “cloudy bags” of day 1
peritonitis, or from uninfected overnight dwell bags as previously
described.27 Cells were counted by hemocytometer and the leukocyte
composition was assessed by ﬂow cytometry (see the following
sections).
Flow cytometry and cell sorting
Cells were stained with LIVE/DEAD Fixable Aqua Stain kit (Life
technologies, Carlsbad, California, USA), before blocking (1% vol/vol
normal mouse serum) and staining of anti-human monoclonal an-
tibodies (together with isotype controls) (Supplementary Table S1).
Cells were acquired on either the Cyan ADP (Beckman-Coulter, Brea,Kidney International (2017) 91, 1088–1103
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California, USA) ﬂow cytometers with Summit software (Beckman-
Coulter) or FlowJo (TreeStar, Ashland, Oregon, USA). The respective
MØs and DCs were puriﬁed by ﬂow cytometry (FACSAria III; BD
Biosciences) based on the same gating strategy for MØ/DC subset
identiﬁcation. The puriﬁed subsets were immediately used in
morphological images, functional assays, and microarray analyses (see
later in this article).
Morphological analysis
Cells were cytospun (Cytospin 3, 300 rpm for 5 minutes; Shandon,
Runcorn, UK), air-dried, stained with Microscopy Hemacolor
(Merck, Millipore, Billerica, Massachusetts, USA), visualized on a
Leica DMLB microscope with DFC490 camera (Leica, Wetzlar,
Germany) and processed using QWin Software (Leica).
RNA isolation and microarray analysis
Total RNAwas extracted from puriﬁed MØs or DCs using miRNeasy
micro kit (Qiagen, Hilden, Germany), according to manufacturer’s
protocol. After reverse-transcription reactions, double-strand DNA
was hybridized on the Affymetrix (Santa Clara, California, USA)
GeneChip Human Gene 1.0 STArray. Detailed information regarding
microarray analysis is described in the Supplementary Material.
Ex vivo phagocytosis assay and respiratory burst activity
Cells were pre-incubated with 3’-(p-aminophenyl) ﬂuorescein
(5 mM ﬁnal concentration; from Life technologies) for 30 minutes at
37 oC, 5% CO2 in the dark, before the addition of 7-hydroxy-9H-
(1,3-dichloro-9,9-dimethylacridin-2-one)–conjugated S epidermidis
(w108 colony-forming units) for 30 minutes at 37 oC, 5% CO2
in the dark. After wash, cells were stained and analyzed with ﬂow
cytometer as described previously.
Antigen-processing and -presenting assay
Assays were performed as previously described with slight modiﬁ-
cations34 (detailed in Supplementary Material). Brieﬂy, MØs or DCs
were loaded with either recombinant Inﬂuenza M1 protein (1 mM)
or M1p58–66 peptide (0.1 mM), before co-culturing with responder
CD8þ T cells. Responder T cells alone and with phorbol myristate
acetate (10 mg/ml) þ ionomycin (1mM) were used as negative and
positive controls, respectively. The co-cultures were incubated for 5
hours at 37C in the presence of Brefeldin-A (10 mg/ml; Sigma-
Aldrich, St. Louis, Missouri, USA). Cells were then stained with
surface antibodies, ﬁxed and permeabilized for intracellular staining
with anti–interferon-ɣ-FITC and analyzed with ﬂow cytometry as
described previously.
Statistical analysis
Statistical analyses were conducted by using the GraphPad Prism
(GraphPad Software, San Diego, California, USA). The statistical
tests used are indicated as appropriate within the text. P values are
denoted or summarized as follows: *P # 0.05; **P # 0.01; and
***P # 0.001. All analyses performed were 2-tailed.
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Supplementary Methods
Figure S1. Peritoneal CD14þ cells and CD1cþ cells involved in distinct
canonical pathways for the up- and downregulated genes. Ingenuity
pathway analysis of the differentially expressed genes comparing
peritoneal CD14þ cells and CD1cþ cells puriﬁed from 5 stable PD
patients. Differentially expressed genes were identiﬁed using right-
tailed Fisher exact test sorted for P < 0.05 and fold change $2
between the 2 populations. Based on these criteria, 192 upregulated
and 236 downregulated genes (CD14þ cells vs. CD1cþ cells) were
identiﬁed. Graphs show the enriched pathways for the up- (A) and
downregulated (B) genes. Blue bars denote the P values (log10) for
each pathway enrichment; –log (P value) cutoff of 1.3 was applied,
meaning that pathways with a P value $ 0.05 are hidden. The orange
squares indicate the ratio of the number of up- and downregulated
genes to the total number of molecules within that pathway repre-
sented by the connecting orange line. The horizontal solid orange
line corresponds to the P ¼ 0.05 threshold.
Figure S2. Peritoneal MØ and DC display distinct transcriptomic
signatures. Heatmaps representing the relative expression of selective
genes encoding key molecules involving major immune functions
such as Toll-like receptors (TLR), c-type lectin receptors (CLR), scav-
enger receptors, Fc receptors, chemokine/receptors, cytokine/re-
ceptors, and molecules responsible for antigen presentation.
Differentially expressed genes selected for analysis were based on
fold change $2, either CD14þ cells versus CD1cþ cells or vice versa,
then clustered on heat maps.
Figure S3. Cytokine production in response to ex vivo microbial
product stimulation. (A) Representative density plots illustrating the
ﬂow-cytometric determination of intracellular cytokine production by
peritoneal MØ/DC from stable PD patients, after ex vivo stimulation
with S epidermidis supernatant (SES) (1:10 dilution) or lipopolysac-
charide (LPS) for 4 hours (tumor necrosis factor [TNF]-a, IL-1b, IL-6) or
24 hours (IL-10), or 22 hours (IL-12p40/p70, in addition to 2 hours of
interferon [IFN]-g priming), in parallel with medium only as unsti-
mulated control. Data are derived from 1 patient representative of
7 stable patients giving similar results. (B) Bar graphs showing the
quantitative comparisons of the intracellular cytokine production
between peritoneal CD14þ MØs and CD1cþ DCs. Cells were cultured
in medium alone or stimulated ex vivo with SES or LPS as described
previously. Positive intracellular cytokine production was determined
by comparison with isotype controls. Data represent mean  SEM
and are derived from 7 stable PD patients. Statistical analysis was
performed by paired t tests.
Figure S4. Flow diagram of longitudinal outcomes of new-starter
PD patients during 1- year follow-up. A total of 50 new-starter PD
patients was enrolled in this study. The reasons for dropout from this
cohort during 1-year follow-up period included receiving kidney
transplantation (n ¼ 12), transferring to other institutions (n ¼ 1),
nondeath technique failure (n ¼ 19), death (n ¼ 3). The number in
each set of parentheses denotes the number of patients under each
deﬁned category.
Figure S5. Flow-cytometric gating strategies to identify different
peritoneal myeloid subsets from PD efﬂuent ﬂuids. Density plots show1101
bas i c re sea r ch C-T Liao et al.: Mononuclear phagocyte phenotype during peritoneal dialysismyeloid cells were pregated on CD116þ populations after exclusion of
doublets, cellular debris, and dead cells. Within these cells, monocytic
cells could be readily identiﬁed as HLA-DRþCD14þ/low/–. Granulocytes
were HLA-DR–CD14–. Other useful surface markers, such as CD16,
CD15, CD66, CCR3, siglec-8, are applied for conﬁrmation of neutrophils
(CD16þCD15þCD66þ) and eosinophils (CD16–CCR3þsiglec-8þ). Data
represent the analysis of peritoneal efﬂuent cells from the ﬁrst ﬂush
bag of a new-starter PD patient. NK, natural killer.
Figure S6. Changes in the number and the proportion of major
peritoneal myeloid subsets during the ﬁrst year of PD therapy. (A)
Data showing the numbers of total peritoneal cells, neutrophils,
eosinophils, and monocytic cells changed during the 1-year follow-up
period. Data were representative of 171 PD samples from 50 patients
at 6 time points (50 samples from 1st ﬂush, 37 samples from 2nd ﬂush,
39 samples from PD start, 20 samples from PD for 3 months, 15
samples from PD for 6 months, and 10 samples from PD for 1 year).
Horizontal bar in each group represents the mean. (B) Graphs
showing the numbers (left) and the proportion (right) of peritoneal
neutrophils, eosinophils, and monocytic cells changed during the
1-year follow-up period. Data were derived from the same samples
from (A). Error bars in each group denote the SEM.
Figure S7. Comparison of 2 microarray datasets. The array data were
generated (or downloaded) as described in the methods section. Our
data were compared with that of Segura et al.41 (A) We compared the
expression of the probesets that were signiﬁcantly regulated in both
our study and the Segura et al.41 dataset (between the 2 peritoneal
subsets reported) (using 2 FDR-corrected P-value thresholds for
regulation in the datasets as indicated). There was a high correlation
between the expression patterns reported by Segura et al.41 and in
our dataset, indicating likely overlap in the cellular identities. (B) The
same data were also represented as a volcano plot to demonstrate
fold change and P value in our dataset.
Table S1. Antibodies used in this study were purchased from BD
Biosciences, Biolegend, eBioscience, or R & D Systems. Biotin-
conjugated antibodies were detected with phycoerythrin
(PE)-TexasRed-, allophycocyanin-, Peridinin-chlorophyll-protein
complex
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.
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